Form 4: CompuGen Ltd. Executive Trades Ordinary Shares

Zurit Levine, SVP of Business Development at CompuGen Ltd., executed a Rule 10b5-1 plan transaction involving the purchase and sale of ordinary shares.

Summary

• Zurit Levine, Senior Vice President of Business Development at CompuGen Ltd. (CGEN), reported transactions on April 24, 2026.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on December 23, 2025.
• Levine acquired 2,000 ordinary shares at a price of $1.15 per share.
• Concurrently, Levine sold 2,000 ordinary shares at a price of $3.20 per share.
• Following these transactions, Levine beneficially owns 29,375 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine executive trading activity under a pre-established plan, without indicating significant positive or negative developments for the company.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned trading activity designed to avoid insider trading concerns.
• The acquisition of shares at a lower price ($1.15) and sale at a higher price ($3.20) suggests a profitable execution within the plan.
• The reporting person continues to hold a significant number of shares (29,375) after the reported transactions.

Negatives

• The filing does not provide specific details on the overall value or profit generated from the sale, only the per-share price and quantity.

Risks

• The value of the remaining 29,375 shares is subject to market fluctuations and the future performance of CompuGen Ltd.
• The Rule 10b5-1 plan itself is subject to the conditions and terms outlined in the plan, which are not fully detailed in this filing.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Management Comments

• The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.
• The option vested 25% on September 30, 2024 and the remainder vests or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing executive stock transactions under Rule 10b5-1 plans are common in the biotechnology and technology sectors, where CompuGen Ltd. operates. These plans are designed to provide executives with a defense against insider trading allegations by establishing pre-determined trading schedules or parameters.

Stakeholder Impact

• Shareholders: The transactions do not directly impact the company's operations or financial health but provide insight into executive compensation and trading strategies.
• Employees: The vesting schedule of the option is tied to continued service, incentivizing employee retention.
• Management: The use of a Rule 10b5-1 plan demonstrates adherence to corporate governance best practices regarding insider trading.

Next Steps

• Continued vesting of the share option in quarterly installments, subject to continued service.
• Potential future transactions under the Rule 10b5-1 plan, if still active and applicable.

Key Dates

Keywords

CompuGen Ltd., CGEN, Form 4, Insider Trading, Rule 10b5-1, Beneficial Ownership, Ordinary Shares, Stock Transaction, Executive Trading, Securities Exchange Act